Lunai Bioworks Inc. (RENB)
(Delayed Data from NSDQ)
$0.14 USD
-0.03 (-18.54%)
Updated Sep 25, 2025 04:00 PM ET
After-Market: $0.14 0.00 (-0.43%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
RENB 0.14 -0.03(-18.54%)
Will RENB be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for RENB based on the 1-3 month trading system that more than doubles the S&P 500.
Other News for RENB
12 Health Care Stocks Moving In Thursday's Intraday Session
Lunai Bioworks (RENB) Enhances Parkinson's Research Program
Lunai Bioworks advances biomarker discovery preclinical program in Parkinson’s
Lunai Bioworks advances biomarker discovery preclinical program in Parkinson's
Is RENB building pressure? NR7 shows up after soaring 5.63%